1. Home
  2. |Insights
  3. |NIST Announces Plan for Federal Engagement in Artificial Intelligence

NIST Announces Plan for Federal Engagement in Artificial Intelligence

Client Alert | 1 min read | 09.20.19

On August 9, 2019, the National Institute of Standards and Technology (NIST) released “U.S. Leadership in AI: A Plan for Federal Engagement in Developing Technical Standards and Related Tools” (the Plan) in response to Executive Order 13859 (EO), as reported on here. In accordance with the EO, the Plan outlines the following priorities for federal engagement: (1) ensure technical standards minimize vulnerability to attacks from malicious actors; (2) reflect federal priorities for innovation, public trust, and public confidence in systems that use artificial intelligence (AI) technologies; and (3) develop international standards to promote and protect those priorities. With emphasis from both public and private sector, NIST calls for flexible AI standards in regulatory and procurement actions, as well as the prioritization of multidisciplinary research and expansive public-private partnerships. Based on the Plan, companies are likely to see an increased number of opportunities to participate and assist the Federal Government in the standard development process, while simultaneously being put on notice that standards in this burgeoning industry may be forthcoming.

Click here to continue reading this blog post.

Contacts

Insights

Client Alert | 6 min read | 04.29.26

CMS Seeks to Expand Interoperability Requirements to Drug Pre-Authorization (FAQ)

On April 10, 2026, the Centers for Medicare and Medicaid Services (CMS) issued a proposed rule (2026 CMS Interoperability Standards and Prior Authorization for Drugs, or CMS-0062-P) outlining the agency’s plans to impose new interoperability requirements on payors participating in certain Medicare and Medicaid programs. As described by the agency in a recent press release, the proposed rule “builds on” prior rulemaking by clarifying and enhancing interoperability requirements for payors’ prior authorization processes, specifically those associated with coverage requests for pharmaceutical therapies....